Cemiplimab (Libtayo, Regeneron) with platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with non-small-cell lung cancer (NSCLC) expressing PD-L1 (in ≥1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:
locally advanced NSCLC who are not candidates for definitive chemoradiation, or
metastatic NSCLC'.
The dosage schedule is available in the summary of product characteristics for cemiplimab.
The list price of cemiplimab is £4,650 for a vial of 350 mg per 7 ml concentrate for solution for infusion (excluding VAT; BNF online accessed February 2025).
The company has a commercial arrangement. This makes cemiplimab available to the NHS with a discount and it would have also applied to this indication if cemiplimab had been recommended. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on the Regeneron webpage on transparency and policies.